Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele (Q36262971)

13 August 2017

Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele (English)

1 reference

13 August 2017

1 reference

Shinjiro Sakamoto

1 reference

13 August 2017

Satoko Matsueda

1 reference

13 August 2017

Shinzo Takamori

1 reference

13 August 2017

Uhi Toh

1 reference

13 August 2017

Masanori Noguchi

1 reference

13 August 2017

Shigeru Yutani

1 reference

13 August 2017

Akira Yamada

1 reference

13 August 2017

Shigeki Shichijo

1 reference

13 August 2017

Teppei Yamada

1 reference

13 August 2017

Shigetaka Suekane

1 reference

13 August 2017

Kouichiro Kawano

1 reference

13 August 2017

Tetsuro Sasada

1 reference

13 August 2017

Noboru Hattori

1 reference

13 August 2017

Nobuoki Kohno

1 reference

13 August 2017

Kyogo Itoh

1 reference

13 August 2017

25 July 2015

1 reference

13 August 2017

1 reference

13 August 2017

106

1 reference

13 August 2017

1 reference

13 August 2017

1257-1263

1 reference

Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

Personalized peptide vaccine for treatment of advanced cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

Phase I Trial of a Personalized Peptide Vaccine for Patients Positive for Human Leukocyte Antigen–A24 With Recurrent or Progressive Glioblastoma Multiforme

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4638024

Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients

22 September 2018

1 reference

12 December 2020

Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens

1 reference

12 December 2020

New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization

1 reference

12 December 2020

Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer

1 reference

12 December 2020

Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination

1 reference

12 December 2020

A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin

1 reference

12 December 2020

Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer

1 reference

12 December 2020

Identifiers

DOI

10.1111/CAS.12757

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

26212219

1 reference